Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)
Dianthus Therapeutics' (DNTH) quarterly Retained Earnings came in at -$336.7 million in Q4 2025, down 317768.87% year-on-year from N/an in Q4 2024, and down 23.66% quarter-over-quarter from -$272.3 million in Q3 2025.
Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$336.7 million for Q4 2025.
- On a quarterly basis, Retained Earnings fell 317768.87% year-over-year to -$336.7 million in Q4 2025; TTM through Dec 2025 was -$336.7 million, a 317768.87% decrease from a year earlier, with the FY2025 full-year figure at -$336.7 million, down 317768.87% from the prior year.
- Retained Earnings fell to -$336.7 million in Q4 2025 per DNTH's latest filing, from -$272.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $106000.0 in Q4 2024 and bottomed at -$434.5 million in Q2 2023.
- The 5-year median for Retained Earnings is -$174.9 million (2024), against an average of -$178.9 million.
- Across the five-year window, Retained Earnings sank 785420.51% in 2021 and soared 125.53% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$325.6 million in 2021, then surged by 85.91% to -$45.9 million in 2022, then soared by 100.1% to $47000.0 in 2023, then surged by 125.53% to $106000.0 in 2024, then sank by 317768.87% to -$336.7 million in 2025.
- Per Business Quant, the three latest DNTH Retained Earnings figures stand at -$336.7 million (Q4 2025), -$272.3 million (Q3 2025), and -$235.5 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Dianthus Therapeutics | 3.37 Bn | 2.97 Bn | - | -336.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -336.73 Mn |
| Sep 30, 2025 | -272.30 Mn |
| Jun 30, 2025 | -235.50 Mn |
| Mar 31, 2025 | -203.90 Mn |
| Dec 31, 2024 | 106,000.00 |
| Sep 30, 2024 | -145.95 Mn |
| Jun 30, 2024 | -120.78 Mn |
| Mar 31, 2024 | -27,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | -78.90 Mn |
| Jun 30, 2023 | -434.50 Mn |
| Mar 31, 2023 | -431.20 Mn |
| Dec 31, 2022 | -45.87 Mn |
| Sep 30, 2022 | -78.90 Mn |
| Jun 30, 2022 | -602,000.00 |
| Mar 31, 2022 | -469,000.00 |
| Dec 31, 2021 | -325.57 Mn |
| Sep 30, 2021 | -306.28 Mn |
| Jun 30, 2021 | -288.80 Mn |
| Mar 31, 2021 | -271.92 Mn |